Why Is Regeneron Pharmaceuticals, Inc. Bucking the Downtrend?

Last week saw a widespread downturn among biotech stocks. Regeneron Pharmaceuticals, however, was able to move modestly higher. Why?

Apr 14, 2014 at 6:30PM

Biotech stocks are awash in a sea of red for the most part right now. Turning to the gory details, 89% of biotechs finished in negative territory last week -- with the vast majority falling by double digits. Although this downturn is certainly impressive in its voracity, we might be better served by taking a closer look at the few companies that were able to tread water in this tumultuous market, to see if there are any lessons that can be applied going forward. With that in mind, let's dig into why Regeneron Pharmaceuticals (NASDAQ:REGN) was able to eke out a modest 1% gain last week in the wake of the general biotech downturn. 

Regeneron's tremendous top-line growth
Regeneron has three commercially available products, namely Eylea, Zaltrap, and Arcalyst. Eylea is by far the company's most significant revenue generator, however, making up 66% of the company's total revenues of $2.1 billion in 2013. Eylea is a drug approved by the Food and Drug Administration for age-related macular degeneration (wet AMD) and macular edema following central retinal vein occlusion. It is marketed by Bayer Healthcare (NASDAQOTH:BAYRY) in ex-U.S. markets, which generated $70 million in milestone payments for Regeneron last year. What's key to understand is that Eylea has been the company's primary growth driver of late, contributing substantially to the overall top-line growth of 53% year over year.


Source: www.drugdiscovery.com.

Looking ahead, the company is hoping to expand the drug's label with potential approvals for diabetic macular edema and macular edema following branch retinal vein occlusion this year. Indeed, Wall Street analysts have already begun to bank on these additional approvals, suggesting that earnings could grow another 57% next year.

To show the importance of Eylea to Regeneron's top-line growth, you need to understand that Zaltrap's worldwide sales came in at roughly $70 million in 2013 as a treatment for metastatic colorectal cancer, with a significant share of this revenue going to Sanofi (NYSE:SNY)per their development agreement. And Arcalyst only generated $17 million in full-year sales for 2013 as a treatment for a host of rare auto-immune disorders.

All told, the lion's share of the Regeneron's remaining income for 2013 came through its research agreements with Sanofi for a host of monoclonal antibodies and with Bayer for additional indications for Eylea.  

A peek into Regeneron's clinical pipeline
Regeneron has a particularly active clinical program with 14 monoclonal antibodies in development and a human genetics initiative launched last January to more fully explore the genetic underpinnings of a diversity of diseases. Among these clinical activities, however, all eyes are on the company's late-stage experimental cholesterol treatment called alirocumab (which is being developed in partnership with Sanofi). Investors are excited about the drug's prospects because it was shown to be clinically superior to Pfizer's (NYSE:PFE) megablockbuster Lipitor in early-stage testing and is expected to become a blockbuster in its own right. The next peek at the late-stage data for alirocumab is expected by mid-year 2014.   

That said, Amgen (NASDAQ:AMGN) and Pfizer are also developing similar cholesterol-lowering drugs, also known as PCSK9 inhibitors. Amgen's PCSK9 inhibitor, called evolocumab, could be under regulatory review with the FDA before year's end and Pfizer's rival named bococizumab recently reported particularly encouraging results in a mid-stage trial. In sum, alirocumab probably won't be the first PCSK9 blocker on the market and will have to compete against some of the industry's biggest players, if it's approved. Of course, there is also the potential issue of adverse neurocognitive side effects for the entire PCSK9 class, which the FDA is looking into (and which could have a material effect on potential approval).

Foolish wrap-up
Regeneron is a curious case because it is showing some strength in the face of the overall weakness among biotechs. I find this particularly surprising given that Regeneron shares are currently trading at more than 13 times annual sales and a forward price-to-earnings ratio of 42 -- that assumes Eylea will continue to grow sales at a breakneck pace over the next year. In other words, this already high forward P/E ratio may still turn out to be overly optimistic. 

In light of Regeneron's comparatively high valuation at the present time, I suspect that the company's continued strength is due to the upcoming data release of alirocumab. Put simply, the market appears to be baking in some of alirocumab's potential future revenue into Regeneron's present valuation. The problem is that Amgen is close to a regulatory filing for evolocumab and Pfizer's bocoizumab is also rapidly advancing in clinical trials. As such, I am doubtful that a single cholesterol-lowering drug will be able to overcome this competition to generate sky-high sales like those of Lipitor in its heyday. In short, you might want to be cautious with Regeneron moving forward, especially in a difficult market environment such as this one.

Looking for the next great stock idea?
There's a huge difference between a good stock and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.

Editor's Note: A previous version of this article incorrectly referred to Eylea as a vaccine. The Fool regrets the error.

George Budwell has no position in any stocks mentioned, and neither does The Motley Fool. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of fool.com.

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to www.fool.com/beginners, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at www.fool.com/podcasts.

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.

Compare Brokers